Chronic Lymphocytic Leukemia Market Outlook and Strategic Insights And Key Business Influencing Factors To 2027 sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
EU Reporter
EAPM: The blood is the life – key work on blood cancers needed with respect to the upcoming European Beating Cancer Plan
Published 2 months ago
Good afternoon, and welcome to the second update of the week from the European Alliance for Personalised Medicine (EAPM). With the upcoming Europe’s Beating Cancer Plan (scheduled for its formal launch on 3 or 4 February, depending on whether DG SANTE or the Commission are correct in their predictions), health discussions will inevitably turn to how the noble aim of the campaign is likely to be achieved, and EAPM Executive Director Dr. Denis Horgan turns his particular attention to cancers of the blood.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
Precipio, Inc.January 20, 2021 GMT
NEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has signed agreements with two of the largest oncology practices in the US, West Cancer Center of Memphis, TN; and New York Cancer & Blood Specialists of New York. During the coming weeks, both practices will be bringing Precipio’s HemeScreen technology in-house. The implementation of HemeScreen will enable these practices to significantly improve turnaround time for important molecular tests for diseases such as MPN (Myeloproliferative Neoplasms), CLL (Chronic Lymphocytic Leukemia) and AML (Acute Myeloid Leukemia), delivering better care to their cancer patients.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Day Two of Bionano’s Next-Generation Cytogenomics Symposium: Saphyr Outperforms Standard .
Bionano GenomicsJanuary 13, 2021 GMT
ADVERTISEMENT
SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) Bionano Genomics, Inc. (Nasdaq: BNGO) announced that day two of its five-day Next-Generation Cytogenomics Symposium featured eight Saphyr users presenting their results and experiences using the Saphyr® system for optical genome mapping (OGM) to analyze the genomes of patients with heme malignancies. The presentations by scientists and clinicians from leading hospitals and medical research institutions in Europe, the US and China discussed results on a variety of blood cancers, including Myelodysplastic Syndromes and a number of acute and chronic leukemias, and all 8 studies showed that Saphyr-based analyses of hematological malignancies can identify actionable variants detected by several cytogenomic